AR031828A2 - Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia - Google Patents
Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapiaInfo
- Publication number
- AR031828A2 AR031828A2 ARP000101632A ARP000101632A AR031828A2 AR 031828 A2 AR031828 A2 AR 031828A2 AR P000101632 A ARP000101632 A AR P000101632A AR P000101632 A ARP000101632 A AR P000101632A AR 031828 A2 AR031828 A2 AR 031828A2
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- compound
- enantiomer
- preparing
- spiro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Procedimientos para la preparacion de compuestos espiro-azabicíclicos que tienen la formula (1), donde R representa hidrogeno o metilo; y n representa 1 o 2; o una sal de adicion de ácido farmacéuticamente aceptable o de un enantiomero del mismo, que comprende (a) preparar un compuesto de formula (1) en el que R representa hidrogeno ciclando un correspondiente compuesto de formula (2), donde n es tal como se ha definido anteriormente; (b) preparar un compuesto de formula (1) mediante la reaccion de un compuesto correspondiente de formula (3), donde n y R son tal como se han definido anteriormente, con un compuesto dador de carbonilo; (c) preparar un compuesto de formula (1) donde R representa metilo mediante la alquilacion de un compuesto correspondiente de formula (1) en el que R representa hidrogeno; o (d) preparar un enantiomero de un compuesto de formula (1) resolviendo el enantiomero a partir de una mezcla de enantiomeros; y cuando se desea o es necesario convertir el compuesto resultante de formula (1), o una sal de adicion de ácido del mismo o un enantiomero del mismo a una sal de adicion de ácido farmacéuticamente aceptable o a un enantiomero del mismo, o viceversa; y procedimiento para preparar composiciones farmacéuticas utiles en terapia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9417084A GB9417084D0 (en) | 1994-08-24 | 1994-08-24 | Compounds useful in therapy |
| GBGB9504627.2A GB9504627D0 (en) | 1995-03-08 | 1995-03-08 | Compounds for use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR031828A2 true AR031828A2 (es) | 2003-10-08 |
Family
ID=26305509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000101632A AR031828A2 (es) | 1994-08-24 | 2000-04-10 | Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US5902814A (es) |
| EP (1) | EP0777671B1 (es) |
| JP (1) | JP3708962B2 (es) |
| KR (1) | KR100366331B1 (es) |
| CN (2) | CN1056846C (es) |
| AR (1) | AR031828A2 (es) |
| AT (1) | ATE192157T1 (es) |
| AU (1) | AU690735B2 (es) |
| BR (1) | BR9508751A (es) |
| CA (1) | CA2196995C (es) |
| CZ (1) | CZ289512B6 (es) |
| DE (1) | DE69516524T2 (es) |
| DK (1) | DK0777671T3 (es) |
| EE (1) | EE03399B1 (es) |
| EG (1) | EG24222A (es) |
| ES (1) | ES2145922T3 (es) |
| FI (1) | FI112868B (es) |
| GR (1) | GR3033878T3 (es) |
| HK (1) | HK1010370A1 (es) |
| HU (1) | HUT77352A (es) |
| IL (1) | IL115039A (es) |
| IS (1) | IS1852B (es) |
| MX (1) | MX9701292A (es) |
| NO (1) | NO307707B1 (es) |
| NZ (1) | NZ292289A (es) |
| PL (1) | PL183933B1 (es) |
| PT (1) | PT777671E (es) |
| RU (1) | RU2148058C1 (es) |
| SA (1) | SA95160370B1 (es) |
| SK (1) | SK282366B6 (es) |
| TR (1) | TR199501053A2 (es) |
| TW (1) | TW397837B (es) |
| UA (1) | UA54375C2 (es) |
| WO (1) | WO1996006098A1 (es) |
Families Citing this family (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5977144A (en) * | 1992-08-31 | 1999-11-02 | University Of Florida | Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines |
| AR013184A1 (es) | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
| US6277870B1 (en) * | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
| SE9900100D0 (sv) * | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| JP4564135B2 (ja) * | 1999-07-26 | 2010-10-20 | 住友化学株式会社 | 高純度フェノチアジン化合物とその製造方法、およびその中間体の製造方法、並びにその中間体の原料の水和物と新規結晶 |
| WO2001066546A1 (fr) * | 2000-03-09 | 2001-09-13 | Mitsubishi Pharma Corporation | Composes spiro, leur procede de preparation et leur utilisation comme medicaments |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| AU2001286938A1 (en) * | 2000-08-28 | 2002-03-13 | Colorado State University Research Foundation | Compounds containing oxazolidinone moiety and uses thereof |
| US6569865B2 (en) | 2001-06-01 | 2003-05-27 | Astrazeneca Ab | Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine |
| JP2005510482A (ja) * | 2001-10-16 | 2005-04-21 | アストラゼネカ・アクチエボラーグ | 線維筋痛症候群の治療方法 |
| DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
| EP1487494A2 (en) * | 2002-02-26 | 2004-12-22 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
| SE0202598D0 (sv) * | 2002-09-02 | 2002-09-02 | Astrazeneca Ab | Alpha-7 Nicotinic receptor agonists and statins in combination |
| EP2062595A1 (en) * | 2002-12-06 | 2009-05-27 | The Feinstein Institute for Medical Research | Inhibition of inflammation using alpha 7 receptor-binding cholinergic agonists |
| US7238715B2 (en) * | 2002-12-06 | 2007-07-03 | The Feinstein Institute For Medical Research | Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists |
| AU2004255920B2 (en) * | 2003-07-08 | 2008-05-15 | Astrazeneca Ab | Spiro [1-azabicyclo [2.2.2] octan-3,5'-oxazolidin]-2'-one derivatives with affinity to the alpha7 nicotinic acetylcholine receptor |
| AU2005225458B2 (en) * | 2004-03-25 | 2008-12-04 | The Feinstein Institutes For Medical Research | Neural tourniquet |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| US20080113983A1 (en) * | 2004-12-15 | 2008-05-15 | Astrazeneca Ab | Nicotinic Acetylcholine Receptor Ligands |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| CN101124012B (zh) | 2004-12-27 | 2012-09-05 | 范因斯坦医学研究院 | 通过电刺激迷走神经治疗炎症性疾病的装置 |
| CN101090895A (zh) * | 2004-12-28 | 2007-12-19 | 阿斯利康(瑞典)有限公司 | 芳基磺酰胺调节剂 |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| JP2009506069A (ja) * | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| US8316104B2 (en) | 2005-11-15 | 2012-11-20 | California Institute Of Technology | Method and apparatus for collaborative system |
| WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
| WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| DE102008015999B4 (de) | 2008-03-27 | 2011-04-21 | Novar Gmbh | Übertragungsweg - Prüfverfahren für eine Gefahrenmeldeanlage |
| WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| US8309577B2 (en) | 2008-04-23 | 2012-11-13 | Bristol-Myers Squibb Company | Quinuclidine compounds as α-7 nicotinic acetylcholine receptor ligands |
| US7863291B2 (en) | 2008-04-23 | 2011-01-04 | Bristol-Myers Squibb Company | Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| NZ590616A (en) | 2008-06-20 | 2012-09-28 | Astrazeneca Ab | Dibenzothiazepine derivatives and use thereof |
| WO2010059617A2 (en) | 2008-11-18 | 2010-05-27 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflamatory stimulation |
| PL2540297T3 (pl) | 2008-11-19 | 2015-12-31 | Forum Pharmaceuticals Inc | Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| US8886339B2 (en) | 2009-06-09 | 2014-11-11 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
| BRPI1014793A2 (pt) * | 2009-05-11 | 2016-04-05 | Envivo Pharmaceuticals Inc | tratamento de distúrbios de cognição com determinados receptores de ácido alfa-7-nicotínico em combinação com inibidores de acetil-colinesterase |
| CN102686595A (zh) | 2009-10-28 | 2012-09-19 | 百时美施贵宝公司 | 作为α-7 烟碱乙酰胆碱受体配体的氮杂二环化合物 |
| US8278320B2 (en) | 2009-10-28 | 2012-10-02 | Bristol-Myers Squibb Company | Azabicyclo[2.2.1]heptane compounds as alpha-7 nicotinic acetylcholine receptor ligands |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| AU2010336337B2 (en) | 2009-12-23 | 2016-02-04 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| EP2563796B1 (en) | 2010-04-30 | 2015-03-18 | Bristol-Myers Squibb Company | Aza-bicyclic amine n-oxide compounds as alpha-7 nicotinic acetylcholine receptor ligand pro-drugs |
| PL3029039T3 (pl) | 2010-05-17 | 2018-04-30 | Forum Pharmaceuticals Inc. | Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu |
| WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| AU2013259871A1 (en) | 2012-05-08 | 2014-11-20 | Forum Pharmaceuticals Inc. | Methods of maintaining, treating or improving cognitive function |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2014122474A1 (en) | 2013-02-07 | 2014-08-14 | Takeda Pharmaceutical Company Limited | Piperidin-1 -yl and azepin-1 -yl carboxylates as muscarinic m4 receptor agonists |
| WO2014202999A1 (en) | 2013-06-21 | 2014-12-24 | Takeda Cambridge Limited | 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors |
| GB201314286D0 (en) | 2013-08-08 | 2013-09-25 | Takeda Pharmaceutical | Therapeutic Compounds |
| GB201318222D0 (en) | 2013-10-15 | 2013-11-27 | Takeda Pharmaceutical | Novel compounds |
| GB201320905D0 (en) | 2013-11-27 | 2014-01-08 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201613864A (en) | 2014-02-20 | 2016-04-16 | Takeda Pharmaceutical | Novel compounds |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| WO2017127756A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Control of vagal stimulation |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| US10661112B2 (en) | 2016-07-25 | 2020-05-26 | Tonal Systems, Inc. | Digital strength training |
| US11745039B2 (en) | 2016-07-25 | 2023-09-05 | Tonal Systems, Inc. | Assisted racking of digital resistance |
| GB201616839D0 (en) | 2016-10-04 | 2016-11-16 | Takeda Pharmaceutical Company Limited | Therapeutic compounds |
| GB201619514D0 (en) | 2016-11-18 | 2017-01-04 | Takeda Pharmaceuticals Co | Novel compounds |
| EP3668402A4 (en) | 2017-08-14 | 2021-05-19 | Setpoint Medical Corporation | VAGUS NERVOUS STIMULATION PRE-SCREENING TEST |
| US10335626B2 (en) | 2017-10-02 | 2019-07-02 | Tonal Systems, Inc. | Exercise machine with pancake motor |
| US10486015B2 (en) | 2017-10-02 | 2019-11-26 | Tonal Systems, Inc. | Exercise machine enhancements |
| US10589163B2 (en) | 2017-10-02 | 2020-03-17 | Tonal Systems, Inc. | Exercise machine safety enhancements |
| US10617903B2 (en) | 2017-10-02 | 2020-04-14 | Tonal Systems, Inc. | Exercise machine differential |
| US11660443B2 (en) | 2018-04-20 | 2023-05-30 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| KR20230012585A (ko) | 2020-05-21 | 2023-01-26 | 더 파인스타인 인스티튜츠 포 메디칼 리서치 | 미주 신경 자극을 위한 시스템들 및 방법들 |
| US11285355B1 (en) | 2020-06-08 | 2022-03-29 | Tonal Systems, Inc. | Exercise machine enhancements |
| US11998804B2 (en) | 2021-04-27 | 2024-06-04 | Tonal Systems, Inc. | Repetition phase detection |
| US11878204B2 (en) | 2021-04-27 | 2024-01-23 | Tonal Systems, Inc. | First repetition detection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4028351A (en) * | 1971-09-07 | 1977-06-07 | Buskine S.A. | Method for the preparation of derivatives of spiro (4,5)-decane and derivatives thus obtained |
| CH601304A5 (es) * | 1974-02-12 | 1978-07-14 | Buskine Sa | |
| GB8808433D0 (en) * | 1988-04-11 | 1988-05-11 | Merck Sharp & Dohme | Therapeutic agents |
| GB8816299D0 (en) * | 1988-07-08 | 1988-08-10 | Merck Sharp & Dohme | Therapeutic agents |
| US5534520A (en) * | 1990-04-10 | 1996-07-09 | Fisher; Abraham | Spiro compounds containing five-membered rings |
| IL97726A (en) * | 1990-04-10 | 1994-12-29 | Israel Inst Biolog Res | Pharmaceutical preparations containing compounds with bridged and unbridged heterocyclic groups connected via spiro-atop with oxazoline and thiazoline groups, and sharp compounds |
| US5073560A (en) * | 1990-07-20 | 1991-12-17 | Fisons Corporation | Spiro-isoxazolidine derivatives as cholinergic agents |
| US5137895A (en) * | 1991-04-29 | 1992-08-11 | A. H. Robins Company, Incorporated | 3-[N-aroyl(or thioaroyl)aminomethyl]-3-quinuclidinols |
-
1995
- 1995-08-22 JP JP50799596A patent/JP3708962B2/ja not_active Expired - Fee Related
- 1995-08-22 WO PCT/SE1995/000937 patent/WO1996006098A1/en active IP Right Grant
- 1995-08-22 US US08/525,575 patent/US5902814A/en not_active Expired - Fee Related
- 1995-08-22 ES ES95930755T patent/ES2145922T3/es not_active Expired - Lifetime
- 1995-08-22 KR KR1019970701159A patent/KR100366331B1/ko not_active IP Right Cessation
- 1995-08-22 BR BR9508751A patent/BR9508751A/pt not_active IP Right Cessation
- 1995-08-22 EP EP95930755A patent/EP0777671B1/en not_active Expired - Lifetime
- 1995-08-22 DK DK95930755T patent/DK0777671T3/da active
- 1995-08-22 DE DE69516524T patent/DE69516524T2/de not_active Expired - Fee Related
- 1995-08-22 HU HU9701965A patent/HUT77352A/hu unknown
- 1995-08-22 AT AT95930755T patent/ATE192157T1/de not_active IP Right Cessation
- 1995-08-22 MX MX9701292A patent/MX9701292A/es unknown
- 1995-08-22 PT PT95930755T patent/PT777671E/pt unknown
- 1995-08-22 PL PL95318760A patent/PL183933B1/pl not_active IP Right Cessation
- 1995-08-22 SK SK216-97A patent/SK282366B6/sk not_active IP Right Cessation
- 1995-08-22 UA UA97031329A patent/UA54375C2/uk unknown
- 1995-08-22 CZ CZ1997392A patent/CZ289512B6/cs not_active IP Right Cessation
- 1995-08-22 RU RU97104165A patent/RU2148058C1/ru not_active IP Right Cessation
- 1995-08-22 AU AU34018/95A patent/AU690735B2/en not_active Ceased
- 1995-08-22 EE EE9700039A patent/EE03399B1/xx not_active IP Right Cessation
- 1995-08-22 CN CN95195518A patent/CN1056846C/zh not_active Expired - Fee Related
- 1995-08-22 NZ NZ292289A patent/NZ292289A/en not_active IP Right Cessation
- 1995-08-22 CA CA002196995A patent/CA2196995C/en not_active Expired - Fee Related
- 1995-08-23 IL IL11503995A patent/IL115039A/xx not_active IP Right Cessation
- 1995-08-23 EG EG70395A patent/EG24222A/xx active
- 1995-08-24 TW TW084108836A patent/TW397837B/zh not_active IP Right Cessation
- 1995-08-24 TR TR95/01053A patent/TR199501053A2/xx unknown
- 1995-11-08 SA SA95160370A patent/SA95160370B1/ar unknown
-
1997
- 1997-02-03 IS IS4424A patent/IS1852B/is unknown
- 1997-02-21 NO NO970800A patent/NO307707B1/no not_active IP Right Cessation
- 1997-02-24 FI FI970762A patent/FI112868B/fi active
-
1998
- 1998-09-26 HK HK98110995A patent/HK1010370A1/xx not_active IP Right Cessation
- 1998-11-09 US US09/188,099 patent/US6051581A/en not_active Expired - Fee Related
-
1999
- 1999-11-08 CN CN99123574A patent/CN1099419C/zh not_active Expired - Fee Related
-
2000
- 2000-04-10 AR ARP000101632A patent/AR031828A2/es unknown
- 2000-07-04 GR GR20000401563T patent/GR3033878T3/el not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR031828A2 (es) | Procedimientos para la preparacion de compuestos espiro-azabiciclicos utiles en terapia | |
| AR017021A1 (es) | Acido 2-hidroxiacetico | |
| ES2071621T3 (es) | Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen. | |
| GB2071088B (en) | Indane derivatives | |
| AU8794291A (en) | New oxazolopyridine derivatives, processes for preparing these and pharmaceutical compositions containing them | |
| ATE229017T1 (de) | Farnesyltransferase-inhibitoren mit piperidinstruktur und verfahren zu ihrer herstellung | |
| CA2336412A1 (en) | Medicament for treatment of diabetes | |
| ES2084339T3 (es) | Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central. | |
| DE3586935D1 (de) | Hemmungsstoffe enkephalinase-b deren herstellung und deren pharmazeutische zusammensetzungen. | |
| RU94037246A (ru) | Применение 2-фенил-3-ароилбензотиофенов для ингибирования разрушения хряща | |
| ES2170759T3 (es) | Derivados de galantamina, un procedimiento para su preparacion y su uso como medicamentos. | |
| JPS5665869A (en) | Novel 22hydroxyalkyll3*4*55trihydroxyypiperidine compound* its manufacture and drug | |
| NO834884L (no) | Fremgangsmaate for fremstilling av farmakologisk aktive nitroalifatiske forbindelser | |
| DE69300453D1 (de) | Isoindolinon-derivat, seine herstellung und dieses enthaltende pharmazeutische zusammen setzungen. | |
| AR008695A1 (es) | Composiciones farmaceuticas estabilizadas, basadas en la asociacion de quinupristina / dalfopristina; procedimiento para prepararlas, utilizacion dedichas composiciones y utilizacion del acido metansulfonico o del acido clorhidrico en la estabilizacion de dichas composiciones. | |
| RU94032285A (ru) | Цефалоспориновые соединения, способ их получения, фармацевтическая композиция | |
| SE9900190D0 (sv) | New compounds | |
| AU532394B2 (en) | Processes | |
| BR0209163A (pt) | Composto e processos para preparar um composto | |
| ATE95180T1 (de) | Berbanderivate und ihre herstellung und pharmazeutische zubereitung. | |
| ES2131219T3 (es) | Solvatos estables de compuestos de avermectina. | |
| GR860045B (en) | Novel piperazine derivatives processes for production thereof and pharmaceutical compositions comprising said compounds as active ingredient | |
| NO903585L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive 1,3-oksaziner. | |
| ATE79259T1 (de) | Prophylaktische und heilende zusammensetzung enthaltende eine 8-chlorbenzothiazepin-verbindung und dessen verwendung. | |
| ES2163806T3 (es) | Proceso para la preparacion de antagonistas de nmda. |